- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01841463
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
September 3, 2014 updated by: Piramal Enterprises Limited
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
- An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered with an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients with Advanced or Inoperable Malignant Melanoma with BRAF Mutation
- The primary objective is to determine the safety, maximum tolerated dose (MTD), and dose limiting toxicity (DLT) of the co-administration of P1446A-05 with vemurafenib, in melanoma patients with BRAF mutation
Study Overview
Status
Suspended
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
South San Francisco, California, United States, 94115
- UCSF Medical Center at Mount Zion
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Anschutz Medical Campus
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20057
- Georgetown-Lombardi Comprehensive Cancer Ctr
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas, MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients having histologically confirmed unresectable (Stage III) or metastatic (Stage IV) malignant melanoma with a positive BRAF mutation result determined by Roche CoDx or local CLIA-certified analysis
- Patients naïve to a selective BRAF inhibitor therapy or must have progressed after therapy on a selective BRAF inhibitor. For patients entering the protocol progressing on vemurafenib therapy, they must be tolerant of the 960 mg po bid dose.
- Tumor biopsies are optional in this study except for patients entering the mandatory biopsy cohorts. Nevertheless tumor biopsies are encouraged, especially in patients with accessible tumors for biopsy to include the collection of formalin-fixed, paraffin-embedded (FFPE) and fresh- frozen tissue (FF) as outlined in the biomarker sections of the protocol. Willingness of patient to give consent of biopsy, should be ascertained
- Patients of ≥ 18 years of age
- Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 or1
- Patients with measurable disease per 'Response Evaluation Criteria In Solid Tumors' (RECIST version 1.1)
- Patients must have normal organ and adequate marrow function
- Patients with ability to swallow and retain oral medication
- Women of childbearing potential and men willing to agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the duration of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilized.
- Negative serum pregnancy test within 10 days prior to commencement of therapy dosing in premenopausal women. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year.
Ability to understand and the willingness to offer a written Informed Consent document prior to the screening procedures for participation into the study
- For Extension phase-
- For patients entering the protocol progressing on vemurafenib therapy, they must be tolerant of the vemurafenib dose selected for the extension phase
Exclusion Criteria:
- Prior malignancy (within the last 2 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or any other cancer for which the patient has been disease-free for at least 2 years
- Patients who have received any prior chemotherapy, radiotherapy, biologic/targeted anti-cancer therapy (one week for BRAF inhibitor for melanoma) or surgery within 4 weeks (6 weeks for monoclonal antibodies, radioactive monoclonal antibodies or any radio-or toxin-immunoconjugates) before Day 1 of Investigational product administration and have not recovered (to < Grade 1) from the toxic effects from any prior therapy
- Patients having received any other investigational agents within 4 weeks prior to Day 1 of Investigational product administration and have not recovered completely (to < Grade 1) from the side effects of the earlier investigational agent
- Anticipated administration of any anti-cancer therapies (chemotherapy, radiation therapy, immunotherapy, biological therapy, hormonal therapy, surgery, and/or tumor embolisation) other than those administered in this study such as BRAF inhibitor
- Patients with symptomatic or untreated leptomeningeal or brain metastases, or spinal cord compression [patients with previous brain metastases will be allowed to enter the trial if metastases have been surgically removed or all known sites of metastases have been treated with stereotactic high dose radiosurgery. Patients must be off corticosteroids for at least one month and have a stable lesion with verification by imaging (CT/MRI) within 28 days prior to Day 1 of Investigational product administration]
- Patients with clinically significant medical condition of malabsorption, inflammatory bowel disease, chronic diarrheal condition, refractory nausea, vomiting or any other condition that will interfere significantly with the absorption of study drugs
- Patients with mean QTc interval >480 msec at screening
- Treatment with drugs with potential to cause dysrhythmias including but not limited to terfenadine, quinidine, procainamide, diisopyramide, sotalol, probucol, bepridil, haloperidol, risperidone and/or indapamide
- Patients on warfarin treatment
- Any condition for which participation in this study as judged by the Investigator to be detrimental to the patient with (such as) inter-current illness including, but not limited to ongoing or active infection, New York Heart Association functional classification class III, or IV heart failure; unstable angina pectoris; cardiac arrhythmia; history of myocardial infarction; uncontrolled hypertension (blood pressure above 160/100 mm Hg despite antihypertensive treatment); coronary artery bypass graft; cerebrovascular accident; transient ischemic attack or pulmonary embolism during the previous 6 months or psychiatric illness/social situations that would jeopardize compliance with study requirements
- Patients with a known immediate or delayed hypersensitivity reaction or idiosyncrasy to any other medication chemically related to P1446A-05 or vemurafenib, or excipients considered to be clinically significant by the investigator
- Nursing woman
- Patients with known HIV positivity or AIDS- related illness, or active Hepatitis B virus, and active Hepatitis C virus
- Patients taking drugs known to prolong the QTc interval who cannot be switched to an alternative drug.
For Extension phase-
- Patients with active second malignancy will be eligible as long as they do not need systemic therapy for the second malignancy
- Patients with active brain metastases will be included in the study as long as the tumor size is less than 1 cm without the requirement of steroid use for neurological symptoms
- Patients with evaluable metastatic disease will be allowed even if there is no measurable disease per RECIST 1.1. In this case patients with many sub centimeter in-transit skin/SQ nodules will be eligible for the biopsy cohort.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: P1446A-05
|
- In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) & vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.
The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group.
The max tolerated dose (MTD) of P1446A-05 & vemurafenib co-administered will be determined.
In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, & 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration.
Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples & undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose and Dose Limiting Toxicity
Time Frame: Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
The study will be conducted in two phases- Phase I (Dose escalation phase), and Extension phase.
In the Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of three to six patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.
Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group.
The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.
In the 'Extension' phase, sixty patients with BRAF V600E/K mutations (forty patients naïve to selective BRAF inhibitor therapy, and twenty progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration.
|
Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Response
Time Frame: Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
- To determine best Overall Response Rate (ORR), Duration of response (DOR), Progression Free Survival (PFS), and Overall Survival (OS) of the co-administration of P1446A 05 and vemurafenib using RECIST version 1.1 in melanoma patients with BRAF mutation
|
Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
Pharmacokinetic (PK)
Time Frame: Cycle1 (Day 15 and 22) and Cycle 2 (Day1,15 and 28)
|
|
Cycle1 (Day 15 and 22) and Cycle 2 (Day1,15 and 28)
|
Biomarker Analysis
Time Frame: Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
|
Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Adil Daud, MD, UCSF Medical Center at Mount Zion
- Principal Investigator: Kevin B Kim, MD, The University of Texas Md Anderson Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (Anticipated)
March 1, 2015
Study Completion (Anticipated)
March 1, 2016
Study Registration Dates
First Submitted
April 17, 2013
First Submitted That Met QC Criteria
April 23, 2013
First Posted (Estimate)
April 26, 2013
Study Record Updates
Last Update Posted (Estimate)
September 4, 2014
Last Update Submitted That Met QC Criteria
September 3, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P1446A-05/72/12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced or Inoperable Malignant Melanoma With BRAF Mutation
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | BRAF Gene MutationUnited States
-
Deciphera Pharmaceuticals LLCNot yet recruitingMelanoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | BRAF Gene Mutation | RAS Mutation | NF1 Mutation | RAF Mutation | CRAF Gene MutationUnited States
-
Novartis PharmaceuticalsRecruitingBRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid TumorJapan
-
Daiichi Sankyo, Inc.PlexxikonTerminatedV600-mutated BRAF Unresectable Melanoma | V600-mutated BRAF Metastatic Melanoma | Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF InhibitorUnited States, Germany, France
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditionsUnited States
-
Novartis PharmaceuticalsCompletedAdvanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 MutationFrance, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingAdvanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,BreastItaly, Spain, United States, France, Korea, Republic of, Japan, Canada, Denmark, Belgium
-
Qilu Hospital of Shandong UniversityNot yet recruitingLocally Advanced or Metastatic Acral Malignant MelanomaChina
-
Ascentage Pharma Group Inc.Merck Sharp & Dohme LLCRecruitingMelanoma | P53 Mutation | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | MDM2 Gene MutationUnited States, Australia
-
Ikena OncologyRecruitingColorectal Cancer | Pancreatic Cancer | Thyroid Carcinoma | Solid Tumor, Adult | Malignant Melanoma | Non-Small Cell Lung Carcinoma | BRAF Gene Mutation | Gliomas, Malignant | Ras (Kras or Nras) Gene Mutation | CRAF Gene MutationUnited States
Clinical Trials on P1446A-05
-
Piramal Enterprises LimitedCompleted
-
Piramal Enterprises LimitedCompletedSolid Tumor | Hematologic MalignancyIndia
-
Piramal Enterprises LimitedDana-Farber Cancer Institute; Norris Cotton Cancer CenterSuspendedRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL)United States
-
Tarsus Pharmaceuticals, Inc.Completed
-
Tarsus Pharmaceuticals, Inc.Active, not recruitingHealthy VolunteerUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Cadila PharnmaceuticalsTerminatedStage III or Stage IV MelanomaUnited States
-
CuraGen CorporationCompleted
-
Meridigen Biotech Co., Ltd.Recruiting
-
Centrexion TherapeuticsCompletedOsteoarthritis, KneeUnited States